FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1999594706> ?p ?o ?g. }

• W1999594706 endingPage "1122" @default.
• W1999594706 startingPage "1114" @default.
• W1999594706 abstract "Current guidelines recommend intravenous prostacyclin as first-line therapy for patients with pulmonary arterial hypertension (PAH) in New York Heart Association/World Health Organization functional class (FC) IV, or combination therapy for patients in any FC who do not respond to monotherapy. We investigated the aggressiveness of therapy in patients enrolled in the REVEAL (Registry to Evaluate Early and Long-Term PAH Disease Management) Registry who deteriorated to FC IV or died.Among 3,515 patients (age ≥ 18 years) in REVEAL with a mean pulmonary artery pressure ≥ 25 mm Hg and pulmonary capillary wedge pressure ≤ 15 mm Hg, we examined three sub-sets: the 487 patients who had a PAH-related death, the larger set of 908 patients who died from any cause (PAH-related, not PAH-related, or unknown), and the 294 patients who were FC I, II, or III at enrollment and later assessed as FC IV.Among patients who died, 56% (n = 272 of 487) and 43% (n = 391 of 908) were receiving intravenous prostacyclin before death in the PAH-related death and all-cause death cohorts, respectively. In the PAH-related death cohort, 60% and 16% of patients were most recently assessed as FC III and IV, respectively; among those assessed as FC IV within 6 months of death, 57.7% (n = 15 of 26) had received intravenous prostacyclin. Because many patients died without an observed assessment of worsening to FC IV, we also evaluated medication use among the cohort of patients who worsened to FC IV during the study. One day before worsening to FC IV, 150 of 294 patients were not receiving intravenous prostacyclin and 70 were receiving only PAH-specific monotherapy; of these, 61% and 67%, respectively, received no additional therapy 90 days later.Intravenous prostacyclin and combination therapy are not consistently used in the most seriously ill patients enrolled in REVEAL after being assessed as FC IV or at the time of death." @default.
• W1999594706 created "2016-06-24" @default.
• W1999594706 creator A5003786773 @default.
• W1999594706 creator A5010219489 @default.
• W1999594706 creator A5032869220 @default.
• W1999594706 creator A5038371358 @default.
• W1999594706 date "2013-11-01" @default.
• W1999594706 modified "2023-10-11" @default.
• W1999594706 title "Treatment of patients with pulmonary arterial hypertension at the time of death or deterioration to functional class IV: Insights from the REVEAL Registry" @default.
• W1999594706 cites W104329758 @default.
• W1999594706 cites W1567116170 @default.
• W1999594706 cites W1840736932 @default.
• W1999594706 cites W1974227996 @default.
• W1999594706 cites W1979969712 @default.
• W1999594706 cites W1994219663 @default.
• W1999594706 cites W2010127845 @default.
• W1999594706 cites W2016305001 @default.
• W1999594706 cites W2023103539 @default.
• W1999594706 cites W2025593289 @default.
• W1999594706 cites W2035384054 @default.
• W1999594706 cites W2037489482 @default.
• W1999594706 cites W2048443661 @default.
• W1999594706 cites W2063285527 @default.
• W1999594706 cites W2070485900 @default.
• W1999594706 cites W2100283402 @default.
• W1999594706 cites W2101386214 @default.
• W1999594706 cites W2102994334 @default.
• W1999594706 cites W2105570450 @default.
• W1999594706 cites W2116060557 @default.
• W1999594706 cites W2127994875 @default.
• W1999594706 cites W2129125190 @default.
• W1999594706 cites W2136203952 @default.
• W1999594706 cites W2138649273 @default.
• W1999594706 cites W2139437349 @default.
• W1999594706 cites W2141987653 @default.
• W1999594706 cites W2148225708 @default.
• W1999594706 cites W2149688277 @default.
• W1999594706 cites W2154332638 @default.
• W1999594706 cites W2160314451 @default.
• W1999594706 cites W2161167348 @default.
• W1999594706 cites W2164435377 @default.
• W1999594706 cites W2169054361 @default.
• W1999594706 cites W2321522617 @default.
• W1999594706 cites W4242547689 @default.
• W1999594706 cites W4242764868 @default.
• W1999594706 cites W4293178741 @default.
• W1999594706 doi "https://doi.org/10.1016/j.healun.2013.08.010" @default.
• W1999594706 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24035189" @default.
• W1999594706 hasPublicationYear "2013" @default.
• W1999594706 type Work @default.
• W1999594706 sameAs 1999594706 @default.
• W1999594706 citedByCount "84" @default.
• W1999594706 countsByYear W19995947062013 @default.
• W1999594706 countsByYear W19995947062014 @default.
• W1999594706 countsByYear W19995947062015 @default.
• W1999594706 countsByYear W19995947062016 @default.
• W1999594706 countsByYear W19995947062017 @default.
• W1999594706 countsByYear W19995947062018 @default.
• W1999594706 countsByYear W19995947062019 @default.
• W1999594706 countsByYear W19995947062020 @default.
• W1999594706 countsByYear W19995947062021 @default.
• W1999594706 countsByYear W19995947062022 @default.
• W1999594706 countsByYear W19995947062023 @default.
• W1999594706 crossrefType "journal-article" @default.
• W1999594706 hasAuthorship W1999594706A5003786773 @default.
• W1999594706 hasAuthorship W1999594706A5010219489 @default.
• W1999594706 hasAuthorship W1999594706A5032869220 @default.
• W1999594706 hasAuthorship W1999594706A5038371358 @default.
• W1999594706 hasConcept C126322002 @default.
• W1999594706 hasConcept C146556889 @default.
• W1999594706 hasConcept C164705383 @default.
• W1999594706 hasConcept C201903717 @default.
• W1999594706 hasConcept C2776432619 @default.
• W1999594706 hasConcept C2778198053 @default.
• W1999594706 hasConcept C2779134260 @default.
• W1999594706 hasConcept C2780930700 @default.
• W1999594706 hasConcept C2780940725 @default.
• W1999594706 hasConcept C2781128415 @default.
• W1999594706 hasConcept C29374701 @default.
• W1999594706 hasConcept C71924100 @default.
• W1999594706 hasConcept C72563966 @default.
• W1999594706 hasConceptScore W1999594706C126322002 @default.
• W1999594706 hasConceptScore W1999594706C146556889 @default.
• W1999594706 hasConceptScore W1999594706C164705383 @default.
• W1999594706 hasConceptScore W1999594706C201903717 @default.
• W1999594706 hasConceptScore W1999594706C2776432619 @default.
• W1999594706 hasConceptScore W1999594706C2778198053 @default.
• W1999594706 hasConceptScore W1999594706C2779134260 @default.
• W1999594706 hasConceptScore W1999594706C2780930700 @default.
• W1999594706 hasConceptScore W1999594706C2780940725 @default.
• W1999594706 hasConceptScore W1999594706C2781128415 @default.
• W1999594706 hasConceptScore W1999594706C29374701 @default.
• W1999594706 hasConceptScore W1999594706C71924100 @default.
• W1999594706 hasConceptScore W1999594706C72563966 @default.
• W1999594706 hasIssue "11" @default.
• W1999594706 hasLocation W19995947061 @default.
• W1999594706 hasLocation W19995947062 @default.
• W1999594706 hasOpenAccess W1999594706 @default.

• next